Conjugated heptavalent pneumococcal vaccine

Annals of Pharmacotherapy

Volumn 36, Issue 9, 2002, Pages 1403-1413

  Pai, Vinita B ^a   Heyneman, Catherine A ^a   Erramouspe, John ^a   Rivera Miranda, Giselle C ^a   Le Duff, Michel ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Heptavalent conjugated pnuemococcal vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; DIPHTHERIA TOXOID; POLYSACCHARIDE; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMERICAN INDIAN; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ESKIMO; FEVER; GRANULOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENICITY; INCIDENCE; INFANT; INJECTION PAIN; MEDICAL LITERATURE; MEDLINE; MONEY; MUSCLE HYPOTONIA; NONHUMAN; OTITIS MEDIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLICATION; SEIZURE; SICKLE CELL ANEMIA; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION; CHILD; COST; GENETICS; HETEROZYGOTE; IMMUNOLOGY; REVIEW;

CARRIER STATE; CHILD; CLINICAL TRIALS; COSTS AND COST ANALYSIS; DIPHTHERIA TOXOID; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES; VACCINES, CONJUGATE;

EID: 0036707921     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A048     Document Type: Article

References (57)

1. Bacterial meningitis in the United States in 1995
2. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
3. Prevalence of various respiratory viruses in the middle ear during acute otitis media
4. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media
5. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management
6. Resistant pneumococci: Protecting patients through judicious use of antibiotics
7. The impact of otitis media
8. Six newly recognized types of Streptococcus pneumoniae
9. Epidemiology of pneumococcal serotypes and conjugated vaccine formulations
10. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugated vaccine
11. Vaccination against Streptococcus pneumoniae in childhood: Lack of demonstrable benefit in young Australian children
12. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines
13. Antibody response to pneumococcal vaccination in children younger than five years of age
14. Pneumococcal carriage and type-specific antibody. Failure of a 14-valent vaccine to reduce carriage in healthy children
15. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugated vaccine is immunogenic in infants and children
16. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid
17. 197 in United States infants
18. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies
19. Thymus-independent and thymus-dependent responses to polysaccharide antigens
20. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory
21. Passive immunization against disease due to Haemophilus influenzae type b: Concentrations of antibody to capsular polysaccharide in high-risk children
22. Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease
23. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugated vaccine in children
24. Otoscopy for the diagnosis of otitis media
25. Efficacy of a pneumococcal conjugated vaccine against acute otitis media
26. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugated vaccines
27. Pneumococcal conjugated vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media
28. 197 among infants with sickle cell disease
29. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence
30. Immunization of children infected with human immunodeficiency virus - Supplementary ACIP statement
31. Projected cost-effectiveness of pneumococcal conjugated vaccination of healthy infants and young children
32. Treatment and prevention of otitis media
33. Preventing pneumococcal disease among infants and young children
34. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugated vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis
35. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
36. Pneumococcal bacteremia in Charleston County, South Carolina. A decade later
37. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990 - Ethnic differences and opportunities for prevention
38. Pneumococcal bacteremia in Monroe County, New York
39. Epidemiology of pneumococcal bacteremia and meningitis during the first 5 years of life in Alaska: Implications for conjugated pneumococcal vaccine use
40. Active laboratory-based surveillance for Streptococcus pneumoniae (pneumococcus) among Navajo people in the American southwest, 1989-1996
41. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population
42. Invasive pneumococcal infection in Baltimore, Md: Implications for immunization policy
43. Immunogenicity of a heptavalent pneumococcal conjugated vaccine in Apache and Navajo indian, Alaska native, and non-native American children aged <2 years
44. Cost-effectiveness of pneumococcal vaccine
45. Comparison of the safety and immunogenicity of a pneumococcal conjugated with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
46. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugated vaccine in children younger than two years with and without human immunodeficiency virus infection
47. Antibody response to measles and rubella vaccine by children with HIV infection
48. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
49. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults
50. 197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults
51. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults
52. Pneumococcal conjugated vaccination for adults: Why it's important for children